Therapeutic advances in leukemia and myelodysplastic syndrome over the past 40 years

Hagop Kantarjian, Susan O'Brien, Jorge Cortes, William Wierda, Stefan Faderl, Guillermo Garcia-Manero, Jean Pierre Issa, Elihu Estey, Michael Keating, Emil J. Freireich

Research output: Contribution to journalReview article

Abstract

Major therapeutic progress has been accomplished in leukemia and myelodysplastic syndrome (MDS) over the past 40 years, which may not be fully appreciated by the larger medical community. The objective of this review was to briefly highlight the treatment breakthroughs in leukemia and MDS. Therapeutic progress happened through better understanding of disease pathophysiologies and rational development of targeted agents, like imatinib mesylate in chronic myeloid leukemia (CML), and through astute, empirical discoveries in the clinic, like all-trans retinoic acid and arsenic trioxide in acute promyelocytic leukemia (APL) and chlorodeoxyadenosine in hairy cell leukemia (HCL). Today, the 5- to 10-year survival rates in patients with APL and HCL exceed 80%. In patients with CML, imatinib therapy has been associated with estimated 5- to 7-year survival rates from 85% to 90%. In patients with adult acute lymphocytic leukemia, modern intensive regimens have improved the 5-year survival rates from 20% up to 40%. In patients with chronic lymphocytic leukemia, chemoimmunotherapy recently produced high rates of quality responses and improved long-term outcome. In younger patients with acute myeloid leukemia (AML), the 5-year survival rates range from 40% to 50%, although elderly AML remains a therapeutic challenge. In patients with MDS, it was recently demonstrated that epigenetic therapy with hypomethylating agents improved survival. Much therapeutic progress has been witnessed in leukemia and MDS, and much more is expected to occur soon.

Original languageEnglish (US)
Pages (from-to)1933-1952
Number of pages20
JournalCancer
Volume113
Issue number7
DOIs
StatePublished - Oct 1 2008
Externally publishedYes

Fingerprint

Myelodysplastic Syndromes
Leukemia
Survival Rate
Hairy Cell Leukemia
Acute Promyelocytic Leukemia
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Acute Myeloid Leukemia
Therapeutics
B-Cell Chronic Lymphocytic Leukemia
Tretinoin
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Epigenomics
Survival

Keywords

  • Acute leukemia
  • Chronic leukemia myelodysplastic syndrome
  • Prognosis
  • Survival
  • Treatment era

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Kantarjian, H., O'Brien, S., Cortes, J., Wierda, W., Faderl, S., Garcia-Manero, G., ... Freireich, E. J. (2008). Therapeutic advances in leukemia and myelodysplastic syndrome over the past 40 years. Cancer, 113(7), 1933-1952. https://doi.org/10.1002/cncr.23655

Therapeutic advances in leukemia and myelodysplastic syndrome over the past 40 years. / Kantarjian, Hagop; O'Brien, Susan; Cortes, Jorge; Wierda, William; Faderl, Stefan; Garcia-Manero, Guillermo; Issa, Jean Pierre; Estey, Elihu; Keating, Michael; Freireich, Emil J.

In: Cancer, Vol. 113, No. 7, 01.10.2008, p. 1933-1952.

Research output: Contribution to journalReview article

Kantarjian, H, O'Brien, S, Cortes, J, Wierda, W, Faderl, S, Garcia-Manero, G, Issa, JP, Estey, E, Keating, M & Freireich, EJ 2008, 'Therapeutic advances in leukemia and myelodysplastic syndrome over the past 40 years', Cancer, vol. 113, no. 7, pp. 1933-1952. https://doi.org/10.1002/cncr.23655
Kantarjian H, O'Brien S, Cortes J, Wierda W, Faderl S, Garcia-Manero G et al. Therapeutic advances in leukemia and myelodysplastic syndrome over the past 40 years. Cancer. 2008 Oct 1;113(7):1933-1952. https://doi.org/10.1002/cncr.23655
Kantarjian, Hagop ; O'Brien, Susan ; Cortes, Jorge ; Wierda, William ; Faderl, Stefan ; Garcia-Manero, Guillermo ; Issa, Jean Pierre ; Estey, Elihu ; Keating, Michael ; Freireich, Emil J. / Therapeutic advances in leukemia and myelodysplastic syndrome over the past 40 years. In: Cancer. 2008 ; Vol. 113, No. 7. pp. 1933-1952.
@article{822df27d7dd54d8a8c965fb26671c9d8,
title = "Therapeutic advances in leukemia and myelodysplastic syndrome over the past 40 years",
abstract = "Major therapeutic progress has been accomplished in leukemia and myelodysplastic syndrome (MDS) over the past 40 years, which may not be fully appreciated by the larger medical community. The objective of this review was to briefly highlight the treatment breakthroughs in leukemia and MDS. Therapeutic progress happened through better understanding of disease pathophysiologies and rational development of targeted agents, like imatinib mesylate in chronic myeloid leukemia (CML), and through astute, empirical discoveries in the clinic, like all-trans retinoic acid and arsenic trioxide in acute promyelocytic leukemia (APL) and chlorodeoxyadenosine in hairy cell leukemia (HCL). Today, the 5- to 10-year survival rates in patients with APL and HCL exceed 80{\%}. In patients with CML, imatinib therapy has been associated with estimated 5- to 7-year survival rates from 85{\%} to 90{\%}. In patients with adult acute lymphocytic leukemia, modern intensive regimens have improved the 5-year survival rates from 20{\%} up to 40{\%}. In patients with chronic lymphocytic leukemia, chemoimmunotherapy recently produced high rates of quality responses and improved long-term outcome. In younger patients with acute myeloid leukemia (AML), the 5-year survival rates range from 40{\%} to 50{\%}, although elderly AML remains a therapeutic challenge. In patients with MDS, it was recently demonstrated that epigenetic therapy with hypomethylating agents improved survival. Much therapeutic progress has been witnessed in leukemia and MDS, and much more is expected to occur soon.",
keywords = "Acute leukemia, Chronic leukemia myelodysplastic syndrome, Prognosis, Survival, Treatment era",
author = "Hagop Kantarjian and Susan O'Brien and Jorge Cortes and William Wierda and Stefan Faderl and Guillermo Garcia-Manero and Issa, {Jean Pierre} and Elihu Estey and Michael Keating and Freireich, {Emil J.}",
year = "2008",
month = "10",
day = "1",
doi = "10.1002/cncr.23655",
language = "English (US)",
volume = "113",
pages = "1933--1952",
journal = "Cancer",
issn = "0008-543X",
publisher = "John Wiley and Sons Inc.",
number = "7",

}

TY - JOUR

T1 - Therapeutic advances in leukemia and myelodysplastic syndrome over the past 40 years

AU - Kantarjian, Hagop

AU - O'Brien, Susan

AU - Cortes, Jorge

AU - Wierda, William

AU - Faderl, Stefan

AU - Garcia-Manero, Guillermo

AU - Issa, Jean Pierre

AU - Estey, Elihu

AU - Keating, Michael

AU - Freireich, Emil J.

PY - 2008/10/1

Y1 - 2008/10/1

N2 - Major therapeutic progress has been accomplished in leukemia and myelodysplastic syndrome (MDS) over the past 40 years, which may not be fully appreciated by the larger medical community. The objective of this review was to briefly highlight the treatment breakthroughs in leukemia and MDS. Therapeutic progress happened through better understanding of disease pathophysiologies and rational development of targeted agents, like imatinib mesylate in chronic myeloid leukemia (CML), and through astute, empirical discoveries in the clinic, like all-trans retinoic acid and arsenic trioxide in acute promyelocytic leukemia (APL) and chlorodeoxyadenosine in hairy cell leukemia (HCL). Today, the 5- to 10-year survival rates in patients with APL and HCL exceed 80%. In patients with CML, imatinib therapy has been associated with estimated 5- to 7-year survival rates from 85% to 90%. In patients with adult acute lymphocytic leukemia, modern intensive regimens have improved the 5-year survival rates from 20% up to 40%. In patients with chronic lymphocytic leukemia, chemoimmunotherapy recently produced high rates of quality responses and improved long-term outcome. In younger patients with acute myeloid leukemia (AML), the 5-year survival rates range from 40% to 50%, although elderly AML remains a therapeutic challenge. In patients with MDS, it was recently demonstrated that epigenetic therapy with hypomethylating agents improved survival. Much therapeutic progress has been witnessed in leukemia and MDS, and much more is expected to occur soon.

AB - Major therapeutic progress has been accomplished in leukemia and myelodysplastic syndrome (MDS) over the past 40 years, which may not be fully appreciated by the larger medical community. The objective of this review was to briefly highlight the treatment breakthroughs in leukemia and MDS. Therapeutic progress happened through better understanding of disease pathophysiologies and rational development of targeted agents, like imatinib mesylate in chronic myeloid leukemia (CML), and through astute, empirical discoveries in the clinic, like all-trans retinoic acid and arsenic trioxide in acute promyelocytic leukemia (APL) and chlorodeoxyadenosine in hairy cell leukemia (HCL). Today, the 5- to 10-year survival rates in patients with APL and HCL exceed 80%. In patients with CML, imatinib therapy has been associated with estimated 5- to 7-year survival rates from 85% to 90%. In patients with adult acute lymphocytic leukemia, modern intensive regimens have improved the 5-year survival rates from 20% up to 40%. In patients with chronic lymphocytic leukemia, chemoimmunotherapy recently produced high rates of quality responses and improved long-term outcome. In younger patients with acute myeloid leukemia (AML), the 5-year survival rates range from 40% to 50%, although elderly AML remains a therapeutic challenge. In patients with MDS, it was recently demonstrated that epigenetic therapy with hypomethylating agents improved survival. Much therapeutic progress has been witnessed in leukemia and MDS, and much more is expected to occur soon.

KW - Acute leukemia

KW - Chronic leukemia myelodysplastic syndrome

KW - Prognosis

KW - Survival

KW - Treatment era

UR - http://www.scopus.com/inward/record.url?scp=54049126614&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=54049126614&partnerID=8YFLogxK

U2 - 10.1002/cncr.23655

DO - 10.1002/cncr.23655

M3 - Review article

C2 - 18798533

AN - SCOPUS:54049126614

VL - 113

SP - 1933

EP - 1952

JO - Cancer

JF - Cancer

SN - 0008-543X

IS - 7

ER -